- Release Date: 24/04/20 10:03
- Summary: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
- Price Sensitive: Yes
- Download Document 144.87KB
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
-
- There are more pages in this discussion • 847 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.020(1.95%) |
Mkt cap ! $1.164B | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.04 | $1.01 | $2.277M | 2.221M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 179090 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 171902 | 23 |
View Market Depth
| Last trade - 11.29am 24/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |